Provided by Tiger Fintech (Singapore) Pte. Ltd.

GeoVax Labs Inc

1.82
+0.06503.71%
Volume:672.66K
Turnover:1.19M
Market Cap:17.13M
PE:-0.24
High:1.84
Open:1.75
Low:1.74
Close:1.75
Loading ...

GeoVax Labs Is Maintained at Buy by D. Boral Capital

Dow Jones
·
16 Jan

GeoVax Labs to initiate Phase 2 clinical study of gedeptin

TIPRANKS
·
16 Jan

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

NewMediaWire
·
15 Jan

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

NewMediaWire
·
13 Jan

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

NewMediaWire
·
08 Jan

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

NewMediaWire
·
06 Jan

Noble Financial Remains a Buy on GeoVax Labs (GOVX)

TIPRANKS
·
10 Dec 2024

GeoVax Labs receives Notice of Allowance for cancer vaccine patent

TIPRANKS
·
09 Dec 2024

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

THOMSON REUTERS
·
09 Dec 2024

GeoVax Labs Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Nov 2024

GeoVax Labs (GOVX) Receives a Buy from Noble Financial

TIPRANKS
·
20 Nov 2024

GeoVax Labs Is Maintained at Buy by D. Boral Capital

Dow Jones
·
20 Nov 2024

BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia

Reuters
·
19 Nov 2024

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology

TIPRANKS
·
19 Nov 2024

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia

THOMSON REUTERS
·
19 Nov 2024

GeoVax Labs Inc - Dsmb Recommends Continuation of Geo-Cm04s1 Vaccine Trial

THOMSON REUTERS
·
19 Nov 2024